Biofrontera Inc. (BFRI)
(Delayed Data from NSDQ)
$1.20 USD
+0.13 (12.15%)
Updated Jul 16, 2024 03:59 PM ET
After-Market: $1.19 -0.01 (-0.83%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth B Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BFRI 1.20 +0.13(12.15%)
Will BFRI be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BFRI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BFRI
Voyager Therapeutics (VYGR) Reports Q1 Loss, Tops Revenue Estimates
Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Misses Revenue Estimates
BFRI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings Estimates
Biofrontera Inc. (BFRI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Biofrontera Inc. (BFRI) Upgraded to Buy: Here's What You Should Know
Other News for BFRI
Biofrontera Unveils RhodoLEDĀ® XL Lamp, Eyes Market Growth
Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLEDĀ® XL Lamp
Biofrontera Inc. announces launch of RhodoLED XL lamp
Biofrontera Stockholders Approve Key Governance Decisions
Analysts Offer Insights on Healthcare Companies: Biofrontera (BFRI), Gilead Sciences (GILD) and Ventyx Biosciences (VTYX)